Cite

    Stern, S., Ward, A. J., Saint-Laurent Thibault, C., Camacho, F., Rahme, E., Naessens, D., Aumais, G., Bernard, E., Bourdages, R., Cohen, A., Pare, P., & Dyrda, P. (2018). cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulation. Journal of medical economics, 21, 27–37. http://access.bl.uk/ark:/81055/vdc_100055485670.0x000020